PR Newswire·Jul 17, 2026, 7:00 AM ET

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Inc. priced an underwritten public offering of 10,003,889 common shares at $9.00 per share & 1,111,111 pre-funded warrants at $8.9999 per warrant.
Gross proceeds from the offering are expected to be approximately $100.0 million before deducting underwriting discounts, commissions, & other expenses.
The offering is scheduled to close on July 20, 2026, subject to customary closing conditions.
Underwriters received a 30-day option to purchase an additional 1,667,250 common shares at the public offering price less underwriting discounts.
Morgan Stanley, J.P. Morgan, Leerink Partners, & Mizuho are acting as joint book-running managers for the transaction.
The securities are being offered pursuant to a Registration Statement on Form S-3 filed with the SEC on November 26, 2025, & declared effective on December 12, 2025.
REGENXBIO is a biotechnology company advancing a late-stage pipeline of one-time gene therapy treatments for rare & retinal diseases.
Contact information for corporate communications & investor relations inquiries was provided for Dana Cormack & George E. MacDougall respectively.